Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/price-cut-on-tb-drug-to-expand-access/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/price-cut-on-tb-drug-to-expand-access/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/price-cut-on-tb-drug-to-expand-access/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/price-cut-on-tb-drug-to-expand-access/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6d934919e1-trace').style.display = (document.getElementById('cakeErr67f6d934919e1-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f6d934919e1-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6d934919e1-code').style.display = (document.getElementById('cakeErr67f6d934919e1-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6d934919e1-context').style.display = (document.getElementById('cakeErr67f6d934919e1-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f6d934919e1-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f6d934919e1-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 64560,
		&#039;title&#039; =&gt; &#039;Price cut on TB drug to expand access&#039;,
		&#039;subheading&#039; =&gt; null,
		&#039;description&#039; =&gt; &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;
&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 20 December, 2022, https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;price-cut-on-tb-drug-to-expand-access&#039;,
		&#039;meta_title&#039; =&gt; &#039;&#039;,
		&#039;meta_keywords&#039; =&gt; &#039;&#039;,
		&#039;meta_description&#039; =&gt; &#039;&#039;,
		&#039;noindex&#039; =&gt; (int) 1,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; null,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 64560,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Price cut on TB drug to expand access&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;multidrug-resistant tuberculosis,MDR TB,Pretomanid,TB Alliance,MedAccess,Viatris,Drugs Controller General of India,National Tuberculosis Elimination Program,NTEP&#039;,
	&#039;metaDesc&#039; =&gt; &#039;-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot; title=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 64560,
	&#039;title&#039; =&gt; &#039;Price cut on TB drug to expand access&#039;,
	&#039;subheading&#039; =&gt; null,
	&#039;description&#039; =&gt; &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;
&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 20 December, 2022, https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;price-cut-on-tb-drug-to-expand-access&#039;,
	&#039;meta_title&#039; =&gt; &#039;&#039;,
	&#039;meta_keywords&#039; =&gt; &#039;&#039;,
	&#039;meta_description&#039; =&gt; &#039;&#039;,
	&#039;noindex&#039; =&gt; (int) 1,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; null,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 64560
$metaTitle = &#039;LATEST NEWS UPDATES | Price cut on TB drug to expand access&#039;
$metaKeywords = &#039;multidrug-resistant tuberculosis,MDR TB,Pretomanid,TB Alliance,MedAccess,Viatris,Drugs Controller General of India,National Tuberculosis Elimination Program,NTEP&#039;
$metaDesc = &#039;-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant...&#039;
$disp = &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot; title=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/price-cut-on-tb-drug-to-expand-access.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Price cut on TB drug to expand access | Im4change.org</title>
    <meta name="description" content="-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Price cut on TB drug to expand access</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p style="text-align:justify">-The Hindu Business Line</p><p style="text-align:justify"><em>Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid</em></p><p style="text-align:justify">A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.</p><p style="text-align:justify">The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.</p><p style="text-align:justify">Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.</p><p style="text-align:justify">Treatment previously recommended has been limited, expensive, toxic, and lengthy &ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.</p><p style="text-align:justify">In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.</p><p style="text-align:justify">Please <a href="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece" title="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece">click here</a> to read more.&nbsp;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6d934919e1-trace').style.display = (document.getElementById('cakeErr67f6d934919e1-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f6d934919e1-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6d934919e1-code').style.display = (document.getElementById('cakeErr67f6d934919e1-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6d934919e1-context').style.display = (document.getElementById('cakeErr67f6d934919e1-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f6d934919e1-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f6d934919e1-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 64560,
		&#039;title&#039; =&gt; &#039;Price cut on TB drug to expand access&#039;,
		&#039;subheading&#039; =&gt; null,
		&#039;description&#039; =&gt; &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;
&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 20 December, 2022, https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;price-cut-on-tb-drug-to-expand-access&#039;,
		&#039;meta_title&#039; =&gt; &#039;&#039;,
		&#039;meta_keywords&#039; =&gt; &#039;&#039;,
		&#039;meta_description&#039; =&gt; &#039;&#039;,
		&#039;noindex&#039; =&gt; (int) 1,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; null,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 64560,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Price cut on TB drug to expand access&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;multidrug-resistant tuberculosis,MDR TB,Pretomanid,TB Alliance,MedAccess,Viatris,Drugs Controller General of India,National Tuberculosis Elimination Program,NTEP&#039;,
	&#039;metaDesc&#039; =&gt; &#039;-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot; title=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 64560,
	&#039;title&#039; =&gt; &#039;Price cut on TB drug to expand access&#039;,
	&#039;subheading&#039; =&gt; null,
	&#039;description&#039; =&gt; &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;
&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 20 December, 2022, https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;price-cut-on-tb-drug-to-expand-access&#039;,
	&#039;meta_title&#039; =&gt; &#039;&#039;,
	&#039;meta_keywords&#039; =&gt; &#039;&#039;,
	&#039;meta_description&#039; =&gt; &#039;&#039;,
	&#039;noindex&#039; =&gt; (int) 1,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; null,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 64560
$metaTitle = &#039;LATEST NEWS UPDATES | Price cut on TB drug to expand access&#039;
$metaKeywords = &#039;multidrug-resistant tuberculosis,MDR TB,Pretomanid,TB Alliance,MedAccess,Viatris,Drugs Controller General of India,National Tuberculosis Elimination Program,NTEP&#039;
$metaDesc = &#039;-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant...&#039;
$disp = &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot; title=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/price-cut-on-tb-drug-to-expand-access.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Price cut on TB drug to expand access | Im4change.org</title>
    <meta name="description" content="-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Price cut on TB drug to expand access</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p style="text-align:justify">-The Hindu Business Line</p><p style="text-align:justify"><em>Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid</em></p><p style="text-align:justify">A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.</p><p style="text-align:justify">The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.</p><p style="text-align:justify">Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.</p><p style="text-align:justify">Treatment previously recommended has been limited, expensive, toxic, and lengthy &ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.</p><p style="text-align:justify">In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.</p><p style="text-align:justify">Please <a href="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece" title="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece">click here</a> to read more.&nbsp;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6d934919e1-trace').style.display = (document.getElementById('cakeErr67f6d934919e1-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f6d934919e1-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6d934919e1-code').style.display = (document.getElementById('cakeErr67f6d934919e1-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f6d934919e1-context').style.display = (document.getElementById('cakeErr67f6d934919e1-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f6d934919e1-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f6d934919e1-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 64560,
		&#039;title&#039; =&gt; &#039;Price cut on TB drug to expand access&#039;,
		&#039;subheading&#039; =&gt; null,
		&#039;description&#039; =&gt; &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;
&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 20 December, 2022, https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;price-cut-on-tb-drug-to-expand-access&#039;,
		&#039;meta_title&#039; =&gt; &#039;&#039;,
		&#039;meta_keywords&#039; =&gt; &#039;&#039;,
		&#039;meta_description&#039; =&gt; &#039;&#039;,
		&#039;noindex&#039; =&gt; (int) 1,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; null,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 64560,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Price cut on TB drug to expand access&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;multidrug-resistant tuberculosis,MDR TB,Pretomanid,TB Alliance,MedAccess,Viatris,Drugs Controller General of India,National Tuberculosis Elimination Program,NTEP&#039;,
	&#039;metaDesc&#039; =&gt; &#039;-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot; title=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 64560,
	&#039;title&#039; =&gt; &#039;Price cut on TB drug to expand access&#039;,
	&#039;subheading&#039; =&gt; null,
	&#039;description&#039; =&gt; &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;
&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 20 December, 2022, https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;price-cut-on-tb-drug-to-expand-access&#039;,
	&#039;meta_title&#039; =&gt; &#039;&#039;,
	&#039;meta_keywords&#039; =&gt; &#039;&#039;,
	&#039;meta_description&#039; =&gt; &#039;&#039;,
	&#039;noindex&#039; =&gt; (int) 1,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; null,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 64560
$metaTitle = &#039;LATEST NEWS UPDATES | Price cut on TB drug to expand access&#039;
$metaKeywords = &#039;multidrug-resistant tuberculosis,MDR TB,Pretomanid,TB Alliance,MedAccess,Viatris,Drugs Controller General of India,National Tuberculosis Elimination Program,NTEP&#039;
$metaDesc = &#039;-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant...&#039;
$disp = &#039;&lt;p style=&quot;text-align:justify&quot;&gt;-The Hindu Business Line&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;&lt;em&gt;Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid&lt;/em&gt;&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &amp;ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Treatment previously recommended has been limited, expensive, toxic, and lengthy &amp;ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.&lt;/p&gt;&lt;p style=&quot;text-align:justify&quot;&gt;Please &lt;a href=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot; title=&quot;https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece&quot;&gt;click here&lt;/a&gt; to read more.&amp;nbsp;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/price-cut-on-tb-drug-to-expand-access.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Price cut on TB drug to expand access | Im4change.org</title>
    <meta name="description" content="-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Price cut on TB drug to expand access</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <p style="text-align:justify">-The Hindu Business Line</p><p style="text-align:justify"><em>Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid</em></p><p style="text-align:justify">A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.</p><p style="text-align:justify">The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.</p><p style="text-align:justify">Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.</p><p style="text-align:justify">Treatment previously recommended has been limited, expensive, toxic, and lengthy &ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.</p><p style="text-align:justify">In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.</p><p style="text-align:justify">Please <a href="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece" title="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece">click here</a> to read more.&nbsp;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 64560,
		'title' => 'Price cut on TB drug to expand access',
		'subheading' => null,
		'description' => '<p style="text-align:justify">-The Hindu Business Line</p>

<p style="text-align:justify"><em>Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid</em></p>

<p style="text-align:justify">A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.</p>

<p style="text-align:justify">The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.</p>

<p style="text-align:justify">Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.</p>

<p style="text-align:justify">Treatment previously recommended has been limited, expensive, toxic, and lengthy &ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.</p>

<p style="text-align:justify">In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.</p>

<p style="text-align:justify">Please <a href="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece">click here</a> to read more.&nbsp;</p>
',
		'credit_writer' => 'The Hindu Business Line, 20 December, 2022, https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'price-cut-on-tb-drug-to-expand-access',
		'meta_title' => '',
		'meta_keywords' => '',
		'meta_description' => '',
		'noindex' => (int) 1,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => null,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 64560,
	'metaTitle' => 'LATEST NEWS UPDATES | Price cut on TB drug to expand access',
	'metaKeywords' => 'multidrug-resistant tuberculosis,MDR TB,Pretomanid,TB Alliance,MedAccess,Viatris,Drugs Controller General of India,National Tuberculosis Elimination Program,NTEP',
	'metaDesc' => '-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant...',
	'disp' => '<p style="text-align:justify">-The Hindu Business Line</p><p style="text-align:justify"><em>Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid</em></p><p style="text-align:justify">A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.</p><p style="text-align:justify">The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.</p><p style="text-align:justify">Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.</p><p style="text-align:justify">Treatment previously recommended has been limited, expensive, toxic, and lengthy &ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.</p><p style="text-align:justify">In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.</p><p style="text-align:justify">Please <a href="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece" title="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece">click here</a> to read more.&nbsp;</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 64560,
	'title' => 'Price cut on TB drug to expand access',
	'subheading' => null,
	'description' => '<p style="text-align:justify">-The Hindu Business Line</p>

<p style="text-align:justify"><em>Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid</em></p>

<p style="text-align:justify">A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.</p>

<p style="text-align:justify">The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.</p>

<p style="text-align:justify">Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.</p>

<p style="text-align:justify">Treatment previously recommended has been limited, expensive, toxic, and lengthy &ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.</p>

<p style="text-align:justify">In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.</p>

<p style="text-align:justify">Please <a href="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece">click here</a> to read more.&nbsp;</p>
',
	'credit_writer' => 'The Hindu Business Line, 20 December, 2022, https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'price-cut-on-tb-drug-to-expand-access',
	'meta_title' => '',
	'meta_keywords' => '',
	'meta_description' => '',
	'noindex' => (int) 1,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => null,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {},
		(int) 8 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 64560
$metaTitle = 'LATEST NEWS UPDATES | Price cut on TB drug to expand access'
$metaKeywords = 'multidrug-resistant tuberculosis,MDR TB,Pretomanid,TB Alliance,MedAccess,Viatris,Drugs Controller General of India,National Tuberculosis Elimination Program,NTEP'
$metaDesc = '-The Hindu Business Line

Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid

A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant...'
$disp = '<p style="text-align:justify">-The Hindu Business Line</p><p style="text-align:justify"><em>Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid</em></p><p style="text-align:justify">A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent.</p><p style="text-align:justify">The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations.</p><p style="text-align:justify">Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM &ndash; a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients.</p><p style="text-align:justify">Treatment previously recommended has been limited, expensive, toxic, and lengthy &ndash; requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said.</p><p style="text-align:justify">In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.</p><p style="text-align:justify">Please <a href="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece" title="https://www.thehindubusinessline.com/news/national/price-cut-on-tb-drug-to-expand-access/article66285690.ece">click here</a> to read more.&nbsp;</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Price cut on TB drug to expand access

-The Hindu Business Line Agreement between Viatris, MedAccess and TBA to slash cost by 34 per cent on pretomanid A new agreement among drugmaker Viatris, MedAccess, and TB Alliance looks to reduce the price of pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34 per cent. The agreement will help expand access to this critical new treatment in more than 140 countries, including those with the highest TB burden, said a joint note from the organisations. Pretomanid (Pa) is used in combination with bedaquiline (B), linezolid (L), and sometimes moxifloxacin (M) to form BPaL and BPaLM – a six-month, all-oral treatment regimen, found to be effective at curing about 90 per cent of multidrug-resistant TB (MDR-TB) patients. Treatment previously recommended has been limited, expensive, toxic, and lengthy – requiring patients to take more than 20 pills per day for 9-20 months. However, with the new WHO guidance on TB treatment, almost all drug-resistant TB patients will now be eligible for the shorter BPaL/BPaLM regimens, the note said. In July 2020, the Drugs Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product. Please click here to read more.